Schizophrenia is a chronic psychotic illness affecting roughly 1% of the population globally. DSM-5 requires two or more of: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms — for at least 1 month with continuous signs for at least 6 months. At least one symptom must be delusions, hallucinations, or disorganized speech.
The aberrant salience hypothesis (Shitij Kapur, 2003) provides the most clinically useful framework. Mesolimbic dopamine hyperactivity attaches salience — meaning, importance, "this matters" — to stimuli that are random or innocuous. The TV becomes meaningful. The neighbor becomes suspicious. Internal speech becomes external and meaningful (auditory hallucinations). The patient is not making things up; their brain's salience-attribution system is firing incorrectly.
Simultaneously, mesocortical dopamine is hypoactive. The PFC is starved of the dopamine it needs for working memory, cognitive control, and signal-to-noise. The patient cannot think clearly, cannot integrate new evidence, cannot organize behavior. This produces the cognitive symptoms (working memory, processing speed, attention) and contributes to negative symptoms (avolition, alogia, anhedonia, asociality, affective blunting).
The dual dysregulation matters clinically. D2-blocking antipsychotics reduce mesolimbic firing (good — calms aberrant salience and positive symptoms) but also reduce already-low mesocortical dopamine (bad — worsens negative and cognitive symptoms). First-generation antipsychotics with strong D2 blockade often help positive symptoms while worsening the rest. Second-generation antipsychotics with 5HT2A antagonism partially preserve mesocortical function.
Coordinated specialty care for first-episode psychosis has the strongest evidence for improving long-term outcomes. Models like NAVIGATE, OnTrackNY, EASA combine pharmacotherapy, individual therapy, family psychoeducation, supported employment/education, case management, peer support. RAISE-ETP and other RCTs show CSC substantially outperforms standard treatment on functioning, symptoms, quality of life. The first two years post-onset are critical — outcomes are heavily shaped by what happens then.
Long-term management: antipsychotic medication is typically lifelong for diagnosed schizophrenia — relapse risk is high with discontinuation. Long-acting injectable (LAI) antipsychotics substantially improve adherence and outcomes; underused. Metabolic monitoring is essential — antipsychotic-induced weight gain, dyslipidemia, diabetes drive elevated cardiovascular mortality.
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia (defined as failure of two adequate antipsychotic trials). Better outcomes than alternatives, including reduced suicide risk. But agranulocytosis risk requires weekly to monthly blood monitoring. The clinical decision to start clozapine is significant; the monitoring is non-negotiable.
When you encounter a patient with schizophrenia, the framework matters. Positive symptoms respond to D2 blockade. Negative and cognitive symptoms are harder. Multidimensional treatment — medication plus psychosocial intervention plus supported employment plus family education — produces the best outcomes. Coordinated specialty care for first-episode psychosis is the evidence-based standard.